BioMimetic announces common stock public offering

Download PDF Copy

Jul 13 2010

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today a public offering of 5,000,000 shares of its common stock. BioMimetic has granted the underwriters an option to purchase up to an additional 15% of shares of common stock to cover over-allotments. BioMimetic expects to use the net proceeds of the offering for development and commercialization of its product pipeline and general corporate purposes.

J.P. Morgan Securities Inc. is acting as the sole lead book-running manager of the offering. Canaccord Genuity and Wedbush PacGrow Life Sciences will serve as co-managers. The offering will be made pursuant to a shelf registration statement that was previously filed with the Securities and Exchange Commission (the "SEC") and was declared effective on September 4, 2009.

Source:

BioMimetic Therapeutics

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Redefining control and consistency in anaerobic microbiome workflows

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

Lasting COVID-19 vulnerability in childhood cancer survivors

Scaling B-cell cloning workflows for antibody development

How microRNA is transforming science: From discovery to diagnostics

Scientists use AI to build mutation-proof antibodies for SARS-CoV-2

New antiviral compounds show broad protection against COVID-19 variants

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.